Fifth, the observation of mosaicism in recurrent driver amplicons in a significant proportion of tumors has clinical implications given that driver amplicon genes are often targets for drug development (e.g., ERBB2, MET, and EGFR) and have been proposed to be good targets for drug development in breast cancer (Cancer Genome Atlas Network, 2012). This evidence concerns the gene ERBB2 and breast carcinoma.